In order to compare the effect of 3,5,3 0 -triiodothyroacetic acid (TRIAC) with those of triiodothyronine (T 3 ) and thyroxine (T 4 ), severely hypothyroid rats (n ¼ 56) were infused over 13 days with 1, 2 or 4 nmol/100 g body weight (BW) per day of T 3 or 2, 4 or 8 nmol/100 g BW per day of T 4 or TRIAC. The 8 nmol/100 g BW per day of T 4 or TRIAC induced the same increase in resting metabolic rate, yet 4 nmol/100 g BW per day of T 3 was more potent (P < 0.05). For inhibiting serum TSH levels, 2 nmol/100 g BW per day of TRIAC were significantly less active than 2 nmol/100 g BW per day of T 4 or 1 nmol/100 g BW per day of T 3 (TRIAC, serum TSH 35.5 Ϯ 5.7; T 3 2.58 Ϯ0.91; T 4 2.12 Ϯ0 .59 ng/ml). At higher doses serum TSH and b-TSH mRNA were unmeasurable.Using serum T 3 levels as covariate, the action of T 3 and T 4 was identical on cardiac monodeiodinase type 1 (5 0 D1) activity and hepatic malic enzyme (Me) mRNA levels and similar for hepatic 5 0 D1 activity. The effect of TRIAC was compared with T 3 by using increasing doses of 1, 2 and 4 nmol/100 g BW per day of T 3 and 2, 4 and 8 nmol/100 g BW per day of TRIAC. ANOVA indicated that there was no major difference between the effects of the hormones since with increasing doses the response of hepatic 5 0 D1 mRNA levels and enzyme activity and Me mRNA remained parallel. However, when studying the effect on cardiac 5 0 D1 activity there was not only a difference for type of treatment (T 3 >TRIAC) but this difference became greater with each increment in dose. Interestingly there was also only a small effect of TRIAC on increase in heart weight compared with T 3 and T 4 . Brain cortex monodeiodinase type 2 (5 0 D2) was mainly inhibited by T 4 infusions. Monodeiodinase type 3 (5 0 D3) was stimulated by T 4 , less so by TRIAC and least by T 3 , expressing probably the local T 3 and TRIAC concentrations.In conclusion, despite apparently similar effects of TRIAC and T 3 and T 4 on hepatic parameters of thyroid hormone action, TRIAC differs considerably in terms of its effects on cardiac 5 0 D1 activity and possibly on other fundamental effects of thyroid hormones on the heart since heart weight increased significantly less with TRIAC than with T 3 or T 4 .
We injected rabbits with purified monoclonal murine immunoglobulin (IgG1) or polyclonal antithyroxine antibodies (anti-T4) and polyclonal anti-triiodothyroacetic acid (anti-Triac) antibodies to stimulate the production of anti-idiotypic antibodies. Purified immunoglobulins from all five rabbits immunized with monoclonal primary antibodies were able to inhibit the interaction between [125I]T4 and the primary antibody. The preimmune sera were inactive. This effect was not due to endogenous T4 contamination or contamination with the injected primary antibody. Half-maximal inhibition of binding of primary antibody with anti-idiotype was between 1.6 and 30 micrograms of total immunoglobulins. Addition of normal mouse IgG1 did not alter the inhibitory effect of the anti-idiotypic antibody, suggesting that this effect is specific. These anti-idiotypic antibodies reacted differently with different polyclonal antibodies, reflecting the heterogeneous nature of polyclonal antibody populations. Polyclonal antibodies were less effective in stimulating anti-idiotypic antibody production. One polyclonal anti-T4 and one anti-Triac antibody produced weak anti-idiotypic antibody that had to be used at a concentration of > 600 micrograms of total immunoglobulins to be inhibitory. Both inhibited the binding of T4 to the monoclonal anti-T4 antibody. However, they were ineffective in inhibiting the function of their own antigen, the polyclonal anti-T4 or anti-Triac antibody. We tested the most potent anti-idiotypic antibodies for their ability to compete with T4 for other T4-binding proteins. Specific inhibition of T4 binding to thyroid-binding globulin was observed with half-maximal effect at approximately 450 micrograms of total IgG.(ABSTRACT TRUNCATED AT 250 WORDS)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.